A leading company in diabetes began phase III studies with the goal of expanding its portfolio with a next-generation basal insulin analog.
Acurian has the most experience in the industry.
We’ve worked in successful trials ranging from diabetic nephropathy to diabetic neuropathy, with diabetics taking specific medications, to diabetics who must have had a CV event.
Acurian is the leader in the patient recruitment and retention industry.
Acurian has recruited and enrolled thousands of patients for more than 60 pharmaceutical and biotech companies representing over 4,500 research sites.